Minerva Shares Plunge After FDA Rejects Schizophrenia Drug Candidate

Minerva Neurosciences suffered a blow to its shares Monday when the FDA issued a Refuse to File letter for the schizophrenia drug roluperidone.

Minerva submitted the New Drug Application for roluperidone to treat negative symptoms of schizophrenia in August. The NDA was built on data from two late-stage trials in patients with moderate to severe negative symptoms of schizophrenia.